argenx Reports Positive Results from ADAPT SERON Study for VYVGART

Argenx Se ( (ARGX) ) has provided an announcement.

On August 25, 2025, argenx announced positive topline results from its ADAPT SERON study of VYVGART in patients with AChR-Ab seronegative gMG. The study met its primary endpoint, showing significant improvement in patients’ MG-ADL scores, and demonstrated VYVGART’s potential as a targeted treatment across all AChR-Ab seronegative subtypes. The company plans to submit a supplemental Biologics License Application to the FDA by the end of 2025, aiming to expand VYVGART’s label to include these patient subtypes. This advancement highlights argenx’s commitment to addressing the unmet needs of the MG community and could significantly impact its industry positioning.

The most recent analyst rating on (ARGX) stock is a Buy with a $850.00 price target. To see the full list of analyst forecasts on Argenx Se stock, see the ARGX Stock Forecast page.

Spark’s Take on ARGX Stock

According to Spark, TipRanks’ AI Analyst, ARGX is a Outperform.

Argenx Se’s strong financial performance and earnings call highlight significant growth and innovation. However, technical analysis indicates potential overbought conditions, and operational inefficiencies and cash flow challenges pose risks. The valuation reflects moderate expectations, balancing growth prospects with current market sentiment.

To see Spark’s full report on ARGX stock, click here.

More about Argenx Se

argenx is a global immunology company dedicated to improving the lives of individuals suffering from severe autoimmune diseases. The company focuses on developing innovative therapies, with its primary product being VYVGART, a treatment for generalized myasthenia gravis (gMG).

Average Trading Volume: 390,784

Technical Sentiment Signal: Buy

Current Market Cap: $40.49B

See more insights into ARGX stock on TipRanks’ Stock Analysis page.